Protara Therapeutics
TARA
25 hedge funds and large institutions have $17.5M invested in Protara Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.
660% more capital inflows, than outflows
Capital inflows: $853K | Capital outflows: $112K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
2.76% more ownership
Funds ownership: 47.26% → 50.02% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
11% less funds holding
Funds holding: 28 → 25 (-3)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pharmstandard International
Luxembourg
|
+$719K |
| 2 |
Renaissance Technologies
New York
|
+$68.3K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$26.5K |
| 4 |
Virtu Financial
New York
|
+$16.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
-$73K |
| 2 |
Wedbush Securities
Los Angeles,
California
|
-$25.9K |
| 3 |
Tower Research Capital (TRC)
New York
|
-$4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.72K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.12K |
TARA Hedge Fund Activity: Q3 2017 in Review
25 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2017, worth a combined $17.5M — up 39% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TARA and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Pharmstandard International, adding an estimated $719K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $73K sold.
- 25 institutional investors held Protara Therapeutics (TARA) as of Q3 2017, down from 28 in Q2 2017.
- Funds reported $17.5M of Protara Therapeutics stock for Q3 2017, up 39% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q3 2017 and 5 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q3 2017 was Pharmstandard International, an estimated $719K added.
- The largest Protara Therapeutics seller in Q3 2017 was Bridgeway Capital Management, an estimated $73K sold.
Based on aggregated 13F filings for Q3 2017.